Amylin: A Novel Obesity Therapy
2 hours ago
- Long-acting amylin analogs are a promising new class of injectable therapy for diabetes and obesity, potentially becoming a first-choice treatment for many patients.
- Amylin is a pancreatic hormone that promotes satiety, slows gastric emptying, reduces glucagon secretion, and prevents the decrease in energy expenditure during weight loss.
- Long-acting amylins offer better gastrointestinal tolerability compared to GLP-1 receptor agonists like semaglutide and tirzepatide, making them an alternative or add-on to incretin therapies.
- Amylin may positively affect bone health by promoting bone formation and inhibiting bone resorption through activation of calcitonin receptors.
- Amylin analogs might better preserve skeletal muscle mass and function compared to incretin therapies, potentially through interactions with satellite cells expressing calcitonin receptors.
- Amylin increases leptin sensitivity, working synergistically with leptin to enhance weight loss, unlike GLP-1 receptor agonists.
- Clinical trials show long-acting amylin analogs like cagrilintide, eloralintide, and petrelintide achieve significant weight loss (10-20%) with mild GI side effects, and combination therapies like CagriSema (cagrilintide + semaglutide) produce up to 22.7% weight loss.
- CagriSema shows no significant worsening of side effects and benefits both people with and without type 2 diabetes, with weight loss not necessarily requiring maximum doses.
- Novel unimolecular GLP-1 and amylin receptor agonists like zenagamtide show over 20% weight loss and good efficacy in reducing A1c, with no plateau at higher doses.
- Long-acting amylin therapies will be valuable for patients who do not reach targets with incretin-based therapies or cannot tolerate them, and they could become first-line for obesity, though GLP-1-based drugs remain preferred for conditions like metabolic dysfunction-associated steatotic liver disease.